(VIANEWS) – The Market ended the session with PCI BIOTECH HOLD (PCIB.OL) jumping 9.71% to kr1.92 on Wednesday while Oslo Børs Benchmark Index_GI jumped 0.3% to kr1,263.82.
PCI BIOTECH HOLD’s last close was kr1.75, 48.53% under its 52-week high of kr3.40.
About PCI BIOTECH HOLD
PCI Biotech Holding ASA, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for the treatment of cancer through its photochemical internalization (PCI) technology platform. The company develops anticancer paradigms, including fimaCHEM, a chemotherapeutics for treatment of cancer; fimaVACC, a T-cell induction technology for therapeutic vaccination, which is in pre-clinical study; and fimaNAc, a nucleic acid therapeutics delivery technology, which is in pre-clinical study. It also offers Amphinex, a photosensitiser fimaporfin. The company has collaborative research programs with Olix Pharmaceuticals, Aposense, IMV Immunovaccine, MDimune, eTheRNA, and Immunicum. PCI Biotech Holding ASA was incorporated in 2007 and is based in Oslo, Norway.
Earnings Per Share
As for profitability, PCI BIOTECH HOLD has a trailing twelve months EPS of kr-0.79.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -42.13%.
Volume
Today’s last reported volume for PCI BIOTECH HOLD is 122906 which is 41.6% below its average volume of 210490.
Revenue Growth
Year-on-year quarterly revenue growth grew by 8.4%, now sitting on 2.99M for the twelve trailing months.
Stock Price Classification
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, PCI BIOTECH HOLD’s stock is considered to be overbought (>=80).
Moving Average
PCI BIOTECH HOLD’s value is below its 50-day moving average of kr2.08 and under its 200-day moving average of kr1.99.
More news about PCI BIOTECH HOLD (PCIB.OL).
